132 results found
Monsalvo S, Sevillano B, Palanicawandar R, et al., 2017, Changes in intensive care for stem cell transplant patients: the need for response criteria at 5 days of full treatment to separate good risk patients and avoid futile interventions, 43rd Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Publisher: NATURE PUBLISHING GROUP, Pages: S278-S278, ISSN: 0268-3369
Khoder A, Palanicawandar R, Atta M, et al., 2017, The choice between stem cell mobilisation with GCSF alone or with GCSF plus chemotherapy may impact on the stem cell transplant service, 43rd Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Publisher: NATURE PUBLISHING GROUP, Pages: S146-S147, ISSN: 0268-3369
Pavlu J, Auner H, Szydlo RM, et al., 2017, Analysis of hematopoietic recovery after autologous transplantation as method of quality control for long-term progenitor cell cryopreservation., Bone Marrow Transplantation, Vol: 52, Pages: 1599-1601, ISSN: 1476-5365
Hematopoietic precursor cells (HPC) are able to restore hematopoiesis after high-dose chemotherapy and their cryopreservation is routinely employed prior to the autologous hematopoietic cell transplantation (AHCT). Although previous studies showed feasibility of long-term HPC storage, concerns remain about possible negative effects on their potency. To study the effects of long-term cryopreservation, we compared time to neutrophil and platelet recovery in 50 patients receiving two AHCT for multiple myeloma at least 2 years apart between 2006 and 2016, using HPC obtained from one mobilization and collection attempt before the first transplant. This product was divided into equivalent fractions allowing a minimum of 2 × 106 CD34+ cells/kg recipient’s weight. One fraction was used for the first transplant after median storage of 60 days (range, 17–165) and another fraction was used after median storage of 1448 days (range, 849–3510) at the second AHCT. Neutrophil recovery occurred at 14 days (median; range, 11–21) after the first and 13 days (10–20) after the second AHCT. Platelets recovered at a median of 16 days after both procedures. Considering other factors, such as disease status, conditioning and HPC dose, this single institution data demonstrated no reduction in the potency of HPC after long-term storage.
Giebel S, Labopin M, Socie G, et al., 2017, CYCLOPHOSPHAMIDE VERSUS ETOPOSIDE IN COMBINATION WITH TOTAL BODY IRRADIATION AS CONDITIONING FOR ADULTS WITH PH(-) ALL UNDERGOING ALLO-HCT. A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT, 22nd Congress of the European-Hematology-Association, Publisher: FERRATA STORTI FOUNDATION, Pages: 326-326, ISSN: 0390-6078
Khoder A, Sever M, Palanicawandar R, et al., 2017, PLERIXAFOR EFFECTIVELY RESCUES BIOSIMILAR G-CSFALONE-BASED STEM CELL MOBILISATION FAILURES, Publisher: ELSEVIER SCI LTD, Pages: S55-S55, ISSN: 1465-3249
Pello OM, Innes AJ, Bradshaw A, et al., 2017, BKV-specific T cells in the treatment of severe refractory haemorrhagic cystitis after HLA-haploidentical haematopoietic cell transplantation, EUROPEAN JOURNAL OF HAEMATOLOGY, Vol: 98, Pages: 632-634, ISSN: 0902-4441
Background:Haemorrhagic cystitis caused by BK virus (BKV) is a known complication of allogeneic haematopoietic cell transplantation (HCT) and is relatively common following HLA-haploidentical transplantation. Adoptive immunotransfer of virus-specific T cells from the donor is a promising therapeutic approach, although production of these cells is challenging, particularly when dealing with low-frequency T cells such as BKV-specific T cells.Case report:Here, we present a patient who, following haploidentical HCT, developed severe BKV haemorrhagic cystitis, resistant to standard therapy. He responded well to adoptive transfer of donor cells enriched in BKV-specific T cells using the new second-generation CliniMACS Prodigy and the Cytokine Capture System from Miltenyi Biotec. Treatment led to full resolution of both the symptoms and viraemia without unwanted complications.Conclusion:Our observations suggest that use of products enriched with BKV-specific T cells generated using this system is safe and efficient in HLA-haploidentical HCT where BKV cystitis can be a serious complication.
Pavlu J, Labopin M, Zoellner AK, et al., 2017, Allogeneic hematopoietic cell transplantation for primary refractory acute lymphoblastic leukemia: A report from the Acute Leukemia Working Party of the EBMT, Cancer, Vol: 123, Pages: 1965-1970, ISSN: 0008-543X
BACKGROUND: Patients with primary refractory acute lymphoblastic leukemia (PREF ALL) who fail to achieve a complete remission(CR) after 2 courses of chemotherapy have a dismal prognosis without undergoing allogeneic hematopoietic cell transplantation(HCT). To the authors’ knowledge, there currently are no data regarding factors influencing transplantation outcomes. METHODS: Theauthors retrospectively studied outcomes of transplantation for cases of PREF ALL reported to European Society for Blood andMarrow Transplantation registry. Eligibility criteria for the current analysis included adult patients who underwent their first HCT forPREF ALL between 2000 and 2012. PREF disease was defined as the failure to achieve a morphological CR after 2 courses of inductionchemotherapy. RESULTS: Data regarding 86 adult patients were analyzed. With a median follow-up of 106 months, the probabilityof survival was 36% at 2 years and 23% at 5 years. The probability of leukemia-free survival was 28% and 17%, respectively, and theprobability of nonrecurrence mortality was 20% and 29%, respectively, at 2 years and 5 years. For 66 patients who achieved a CR(77%), the survival at 2 years and 5 years was 36% and 29%, respectively. In multivariate analysis, use of total body irradiation wasfound to be associated with improved survival. Total body irradiation and infusion of female hematopoietic cells into male recipientswas associated with improved leukemia-free survival. These findings were incorporated into a scoring system that identified 3 groups(those with 2, 1, or no prognostic factors) with survival rates of 57%, 22%, and 8%, respectively. CONCLUSIONS: Although overall thesepatients would clearly benefit from the introduction of novel antileukemic therapies, the data from the current study support the useof allogeneic HCT in selected patients with PREF ALL.
Freeman S, Hodgkinson A, Nagra S, et al., 2017, Tracking MRD together with LSC Enriched Populations to Predict Transplant Outcomes in AML, ANNALS OF HEMATOLOGY, Vol: 96, Pages: S23-S24, ISSN: 0939-5555
Pavlu J, Labopin M, Tischer J, et al., 2016, Allogeneic Hematopoietic Stem Cell Transplantation for Primary Refractory Acute Lymphoblastic Leukemia - a Report from the Acute Leukemia Working Party of the EBMT, 58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Publisher: AMER SOC HEMATOLOGY, ISSN: 0006-4971
Patel A, Szydlo RM, Auner HW, et al., 2016, C-reactive protein prior to myeloablative allogeneic haematopoietic cell transplantation identifies patients at risk of early- and long-term mortality, British Journal of Haematology, Vol: 180, Pages: 889-892, ISSN: 1365-2141
Pello O, Bradshaw A, Innes AJ, et al., Clinical Efficacy of BK Virus Specific T-Cells in Treatment of Severe Refractory Hemorrhagic Cystitis after HLA Haploidentical Transplantation, 59th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, Publisher: American Society of Hematology, Pages: 5726-5726, ISSN: 0006-4971
Avenoso D, Bradshaw A, Innes AJ, et al., Microbial Contamination of Haematopoietic Stem Cell Products: A Single Centre Experience, 59th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, Publisher: American Society of Hematology, Pages: 5741-5741, ISSN: 0006-4971
Beckerson J, Szydlo RM, Hickson M, et al., Impact of Nutrition on Non-Relapse Mortality and Acute Graft Versus Host Disease during Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies, 59th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, Publisher: American Society of Hematology, Pages: 2226-2226, ISSN: 0006-4971
Monsalvo S, Sevillano B, Innes AJ, et al., The Intensive Care Trial for Critically Ill Onco-Haematologic Patients: The Need for Response Criteria at 5 Days of Full Treatment to Separate Good Risk Patients and Avoid Futile Intensive Care Interventions, 59th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, Publisher: American Society of Hematology, Pages: 5987-5987, ISSN: 0006-4971
Rohman PJ, Szydlo RM, Hobbs E, et al., Preconditioning Neutropenia Is a Key Prognostic Factor in Allogeneic Hematopoietic Cell Transplantation for High Risk Acute Myeloid Leukemia, 59th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, Publisher: American Society of Hematology, Pages: 3411-3411, ISSN: 0006-4971
Patel A, Jhanji S, Pavlu J, et al., 2016, Mesenchymal stromal stem cell (MSC) immunotherapy for experimental septic shock: systematic review and meta-analysis with trial sequential analysis of mortality, 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation, Publisher: Nature Publishing Group, Pages: S129-S129, ISSN: 1476-5365
Patel A, Szydlo R, Auner H, et al., 2016, C-reactive protein (CRP) prior to myeloablative allogeneic haematopoietic stem cell transplantation is associated with early and long term survival to five years, 42nd Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, Publisher: NATURE PUBLISHING GROUP, Pages: S213-S214, ISSN: 0268-3369
Innes A, Apperley J, Allwood Z, et al., 2016, Development of acute graft-versus-host disease post allogeneic stem cell transplantation results in significant episodes of recurrent and prolonged hospitalisations which are with associated a significant economic burden to stem cell transplant units, 42nd Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, Publisher: Nature Publishing Group, Pages: S575-S576, ISSN: 1476-5365
Bain BJ, Heller M, Toma S, et al., 2015, The cytological features of NPM1-mutated acute myeloid leukemia, AMERICAN JOURNAL OF HEMATOLOGY, Vol: 90, Pages: 560-560, ISSN: 0361-8609
Vanhinsbergh LJ, Fleming C, Babb A, et al., 2015, Azacitidine use in North West London: an update, 55th Annual Scientific Meeting of the British-Society-for-Haematology, Publisher: WILEY-BLACKWELL, Pages: 80-80, ISSN: 0007-1048
Sevillano B, Pavlu J, Szydlo R, et al., 2015, LACE-conditioned allogeneic transplantation for high-risk haematological malignancies: treatment outcomes in 62 patients from a single centre, 41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, Publisher: NATURE PUBLISHING GROUP, Pages: S223-S223, ISSN: 0268-3369
Farah N, Szydlo R, Mitul P, et al., 2015, A Study to Validate the Rationale and Efficacy of a Pre-emptive approach to the management of Cytomegalovirus (CMV) reactivation post allogeneic haematopoietic stem cell transplantation (HSCT), 41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, Publisher: NATURE PUBLISHING GROUP, Pages: S409-S410, ISSN: 0268-3369
Stringaris K, Sekine T, Khoder A, et al., 2014, Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia, HAEMATOLOGICA, Vol: 99, Pages: 836-847, ISSN: 0390-6078
Palani R, Lasa M, Giles C, et al., 2014, HIGH DOSE ETOPOSIDE/GCSF IS A SAFE AND EFFECTIVE MOBILIZATION REGIMEN IN MULTIPLE MYELOMA: A SINGLE-INSTITUTION EXPERIENCE, 40th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation, Publisher: NATURE PUBLISHING GROUP, Pages: S534-S534, ISSN: 0268-3369
King C, Aylin P, Moore LSP, et al., 2014, Syndromic surveillance of surgical site infections - A case study in coronary artery bypass graft patients, JOURNAL OF INFECTION, Vol: 68, Pages: 23-31, ISSN: 0163-4453
Garnett C, Apperley JF, Pavlů J, 2013, Treatment and management of graft-versus-host disease: improving response and survival., Ther Adv Hematol, Vol: 4, Pages: 366-378, ISSN: 2040-6207
Graft-versus-host disease (GVHD) is a significant cause of morbidity and mortality following allogenic haematopoietic stem-cell transplantation and thus the focus of much ongoing research. Despite considerable advances in our understanding of the pathophysiology, diagnosis and predisposing factors for both acute and chronic forms of the disease, a standardised therapeutic strategy is still lacking. There is good evidence for initial treatment of both acute and chronic forms of the disease with corticosteroid therapy. However, the most effective approach to steroid-refractory disease remains controversial, with current practice based mainly on smaller studies and varying considerably between local institutions. Timely diagnosis, multidisciplinary working and good supportive care, including infection prophylaxis, are clearly important in optimizing response and survival in such patients. It is hoped that in the future systematic research strategies and the identification of novel therapeutic targets may improve outcome further. The following review aims to outline some of the existing options for the treatment and management of acute and chronic GVHD.
Tawana K, Renneville A, Wang J, et al., 2013, Familial AML With Germline CEBPA Mutations: Extended Clinical Outcomes and Analysis Of Secondary Mutations Using Whole Exome Sequencing, 55th Annual Meeting of the American-Society-of-Hematology, Publisher: AMER SOC HEMATOLOGY, ISSN: 0006-4971
Auner HW, Szydlo R, Rone A, et al., 2013, Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation, LEUKEMIA & LYMPHOMA, Vol: 54, Pages: 2200-2204, ISSN: 1042-8194
Innes AJ, Beattie R, Sergeant R, et al., 2013, Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT, BONE MARROW TRANSPLANTATION, Vol: 48, Pages: 1324-1328, ISSN: 0268-3369
Deplano S, May PC, Pavlu J, 2013, Double minutes with MYC amplification in a patient with chronic myelomonocytic leukaemia transformed into acute myeloid leukaemia, BRITISH JOURNAL OF HAEMATOLOGY, Vol: 162, Pages: 720-720, ISSN: 0007-1048
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.